Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52,715 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Significance of targeting DNMT3A mutations in AML.
Huang G, Cai X, Li D. Huang G, et al. Among authors: li d. Ann Hematol. 2024 Jul 30. doi: 10.1007/s00277-024-05885-8. Online ahead of print. Ann Hematol. 2024. PMID: 39078434 Review.
Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
Zhou H, Yin Q, Jin J, Liu T, Cai Z, Jiang B, Li D, Sun Z, Li Y, He Y, Ma L, Gao S, Hu J, He A, Du X, Liu D, Zhang X, Ke X, Zhuang J, Han Y, Wang X, Chen Y, Gordon P, Yu D, Zugmaier G, Wang J. Zhou H, et al. Among authors: li d, li y. Hematology. 2022 Dec;27(1):917-927. doi: 10.1080/16078454.2022.2111992. Hematology. 2022. PMID: 36000952 Free article.
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.
Wang T, Sun X, Qiu L, Su H, Cao J, Li Z, Song Y, Zhang L, Li D, Wu H, Zhang W, Li J, Zhou K, Zhou H, Yang Y, Li Z, Cen H, Cai Z, Zhang Z, Fu W, Jin J, Li F, Wu W, Gu X, Zhu W, Liu L, Li Z, Yi S, Bao H, Xu Z, Qiu L. Wang T, et al. Among authors: li f, li d, li z, li j. Clin Cancer Res. 2023 Apr 14;29(8):1440-1449. doi: 10.1158/1078-0432.CCR-22-2939. Clin Cancer Res. 2023. PMID: 36735519 Free PMC article. Clinical Trial.
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis.
Song Y, Zhou K, Zou D, Li D, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Zhou D, Tam CS, Simpson D, Wang M, Phillips TJ, Opat S, Fang C, Sun S, Zhu J. Song Y, et al. Among authors: li d. Cancer Med. 2023 Sep;12(18):18643-18653. doi: 10.1002/cam4.6473. Epub 2023 Sep 14. Cancer Med. 2023. PMID: 37705497 Free PMC article.
52,715 results
You have reached the last available page of results. Please see the User Guide for more information.